Evidence concerning insulin, thiazolidinediones, and sulfonylureas is less robust, while dipeptidyl peptidase-4 inhibitors may exacerbate pancreatic neoplasms [139]. This evidence concerns the gene DPP4 and pancreatic neoplasm.